Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

Bernard L, Belisle C, Mollica L, Provost S, Roy DC, Gilliland DG, Levine RL, Busque L.

Leukemia. 2009 Feb;23(2):287-91. doi: 10.1038/leu.2008.319.

2.

Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.

Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.

Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007.

PMID:
23542632
3.

Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.

Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC.

Acta Haematol. 2013;130(3):181-7. doi: 10.1159/000348413.

PMID:
23751441
4.

Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.

Sun T, Zhang L.

Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):374-81. doi: 10.1177/1076029612453761. Review.

PMID:
22826442
5.

[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].

Chen YX, Li Y, Zhang LY, Liu B.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1329-33. Review. Chinese.

PMID:
22040998
6.

Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.

Spanoudakis E, Bazdiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, Xanthopoulidis G, Moustakidis E, Mantzourani S, Bourikas G, Tsatalas C.

Leuk Res. 2011 Apr;35(4):459-64. doi: 10.1016/j.leukres.2010.07.042.

PMID:
20828816
7.

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.

de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F.

Oncotarget. 2016 Feb 9;7(6):6948-59. doi: 10.18632/oncotarget.6851.

8.

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Yonal I, Pinarbas─▒ B, Hindilerden F, Hancer VS, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R.

J Thromb Thrombolysis. 2012 Oct;34(3):388-96.

PMID:
22569900
9.

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Chen E, Mullally A.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):268-76. doi: 10.1182/asheducation-2014.1.268. Review.

PMID:
25696866
10.

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, Shirane S, Tsutsui M, Noguchi M, Koike M, Imai K, Kirito K, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Araki M, Komatsu N.

Int J Hematol. 2014;99(5):625-34. doi: 10.1007/s12185-014-1567-1.

PMID:
24677207
11.

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.

Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003.

PMID:
19615425
12.

Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.

Martin SE, Sausen M, Joseph A, Kingham BF, Martin ES.

Cancer Genet. 2012 Jun;205(6):295-303. doi: 10.1016/j.cancergen.2012.03.006.

PMID:
22749035
13.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698
14.

Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease.

Huijsmans CJ, Poodt J, Damen J, van der Linden JC, Savelkoul PH, Pruijt JF, Hilbink M, Hermans MH.

PLoS One. 2012;7(7):e38362. doi: 10.1371/journal.pone.0038362.

15.

[JAK2V617F mutation and TNF-╬▒ expression in myeloproliferative neoplasms and their correlation].

Sun CC, Li Y, Tian WJ, Chen YJ, Zhang LY, Liu X, Shan NN.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1022-6. doi: 10.7534/j.issn.1009-2137.2014.04.025. Chinese.

PMID:
25130821
16.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative..

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826.

17.

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.

Minnucci G, Amicarelli G, Salmoiraghi S, Spinelli O, Guinea Montalvo ML, Giussani U, Adlerstein D, Rambaldi A.

Haematologica. 2012 Sep;97(9):1394-400. doi: 10.3324/haematol.2011.056184.

18.

Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.

Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.

Int J Lab Hematol. 2015 Apr;37(2):181-9. doi: 10.1111/ijlh.12257.

PMID:
24845343
19.

Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, Au KL, Wong KF, Chu RW, Yu PH, Chow EY, Leung KF, Tsoi WC, Yung BY.

BMC Genet. 2014 Dec 20;15:147. doi: 10.1186/s12863-014-0147-y.

20.

[JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].

Chen YX, Li Y, Zhang LY, Liu X, Shan NN.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1398-404. Chinese.

PMID:
23257441

Supplemental Content

Support Center